Somatostatin receptor activity assessed by
Humans
Neuroendocrine Tumors
/ metabolism
X-linked Nuclear Protein
/ metabolism
Receptors, Somatostatin
/ metabolism
Gallium Radioisotopes
Retrospective Studies
Adaptor Proteins, Signal Transducing
/ analysis
Pancreatic Neoplasms
/ metabolism
Positron-Emission Tomography
Molecular Chaperones
/ metabolism
Co-Repressor Proteins
/ metabolism
68Ga-DOTA-peptides
ATRX
DAXX
PET
Pancreatic neuroendocrine tumor
Predictive value
Preoperative
Risk assessment
Somatostatin receptor activity
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
18
01
2023
accepted:
18
03
2023
medline:
5
7
2023
pubmed:
4
4
2023
entrez:
3
4
2023
Statut:
ppublish
Résumé
To evaluate the role of This retrospective study included 72 consecutive patients with PanNET (January 2018-March 2022) who underwent to Forty-two/72 patients had a G1, 28/72 a G2, and 2/72 a G3 PanNET. Seven/72 patients had DAXX LoE, 10/72 ATRX LoE, and 2/72 DAXX/ATRX LoE. SRD and TLSRD could predict DAXX LoE (p = 0.002, p = 0.018, respectively). By evaluating SRD in combination with radiological diameter, only SRD maintained statistical significance (multivariate logistic regression: p = 0.020, OR = 1.05), providing the best prediction (AUC-ROC = 79.01%; cut-off = 46.96; sensitivity = 77.78%; specificity = 88.89%). In the sub-analysis performed on 55 patients with biopsy availability, SRD demonstrated its role in providing useful and additional information (multivariate logistic regression: SRD p = 0.007; grade p = 0.040). SRD has a predictive role on DAXX LoE in PanNETs, with higher probability of LoE at increasing SRD values. SRD provides complementary/additional information to grade assessed on biopsy material, and the combined use of these approaches might support patients' management by preoperatively identifying subjects with more aggressive diseases.
Identifiants
pubmed: 37010579
doi: 10.1007/s00259-023-06210-7
pii: 10.1007/s00259-023-06210-7
doi:
Substances chimiques
Edotreotide
U194AS08HZ
X-linked Nuclear Protein
EC 3.6.4.12
Receptors, Somatostatin
0
Gallium Radioisotopes
0
Adaptor Proteins, Signal Transducing
0
ATRX protein, human
EC 3.6.4.12
DAXX protein, human
0
Molecular Chaperones
0
Co-Repressor Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2818-2829Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Lee MR, Harris C, Baeg KJ, Aronson A, Wisnivesky JP, Kim MK. Incidence trends of gastroenteropancreatic neuroendocrine tumors in the United States. Clin Gastroenterol Hepatol. 2019;17:2212-7 e1. https://doi.org/10.1016/j.cgh.2018.12.017 .
doi: 10.1016/j.cgh.2018.12.017
pubmed: 30580091
Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, et al. ENETS Consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. 2017;105:255–65. https://doi.org/10.1159/000464292 .
doi: 10.1159/000464292
pubmed: 28237989
Falconi M, Bartsch DK, Eriksson B, Kloppel G, Lopes JM, O’Connor JM, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95:120–34. https://doi.org/10.1159/000335587 .
doi: 10.1159/000335587
pubmed: 22261872
Partelli S, Muffatti F, Andreasi V, Giannone F, Rossi G, Palumbo D, et al. A single-center prospective observational study investigating the accuracy of preoperative diagnostic procedures in the assessment of lymph node metastases in nonfunctioning pancreatic neuroendocrine tumors. Ann Surg. 2022. https://doi.org/10.1097/SLA.0000000000005615 .
doi: 10.1097/SLA.0000000000005615
pubmed: 36177837
Cives M, Partelli S, Palmirotta R, Lovero D, Mandriani B, Quaresmini D, et al. DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. Sci Rep. 2019;9:18614. https://doi.org/10.1038/s41598-019-55156-0 .
doi: 10.1038/s41598-019-55156-0
pubmed: 31819132
pmcid: 6901561
Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, et al. Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival. Clin Cancer Res. 2017;23:1598–606. https://doi.org/10.1158/1078-0432.CCR-16-1147 .
doi: 10.1158/1078-0432.CCR-16-1147
pubmed: 27663587
Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146:453-60 e5. https://doi.org/10.1053/j.gastro.2013.10.020 .
doi: 10.1053/j.gastro.2013.10.020
pubmed: 24148618
Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543:65–71. https://doi.org/10.1038/nature21063 .
doi: 10.1038/nature21063
pubmed: 28199314
Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, et al. Alternative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clin Cancer Res. 2017;23:600–9. https://doi.org/10.1158/1078-0432.CCR-16-1113 .
doi: 10.1158/1078-0432.CCR-16-1113
pubmed: 27407094
Marinoni I. Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation? Gut. 2022;71:847–8. https://doi.org/10.1136/gutjnl-2021-324664 .
doi: 10.1136/gutjnl-2021-324664
pubmed: 33975869
Takumi K, Fukukura Y, Higashi M, Ideue J, Umanodan T, Hakamada H, et al. Pancreatic neuroendocrine tumors: correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. Eur J Radiol. 2015;84:1436–43. https://doi.org/10.1016/j.ejrad.2015.05.005 .
doi: 10.1016/j.ejrad.2015.05.005
pubmed: 26022520
Tacelli M, Petrone MC, Capurso G, Muffatti F, Andreasi V, Partelli S, et al. Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: possible clinical impact of misclassification. Endosc Ultrasound. 2021;10:372–80. https://doi.org/10.4103/EUS-D-20-00261 .
doi: 10.4103/EUS-D-20-00261
pubmed: 34677159
pmcid: 8544016
Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol. 2012;56:40–7. https://doi.org/10.1111/j.1754-9485.2011.02327.x .
doi: 10.1111/j.1754-9485.2011.02327.x
pubmed: 22339744
Mapelli P, Partelli S, Salgarello M, Doraku J, Pasetto S, Rancoita PMV, et al. Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. Nucl Med Commun. 2020;41:896–905. https://doi.org/10.1097/MNM.0000000000001236 .
doi: 10.1097/MNM.0000000000001236
pubmed: 32796478
Mapelli P, Partelli S, Salgarello M, Doraku J, Muffatti F, Schiavo Lena M, et al. Dual tracer 68Ga-DOTATOC and 18F-FDG PET improve preoperative evaluation of aggressiveness in resectable pancreatic neuroendocrine neoplasms. Diagnostics (Basel). 2021;11. https://doi.org/10.3390/diagnostics11020192 .
Mapelli P, Bezzi C, Palumbo D, Canevari C, Ghezzo S, SamanesGajate AM, et al. (68)Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours. Eur J Nucl Med Mol Imaging. 2022;49:2352–63. https://doi.org/10.1007/s00259-022-05677-0 .
doi: 10.1007/s00259-022-05677-0
pubmed: 35156146
Abdulrezzak U, Kurt YK, Kula M, Tutus A. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. Nucl Med Commun. 2016;37:874–81. https://doi.org/10.1097/MNM.0000000000000522 .
doi: 10.1097/MNM.0000000000000522
pubmed: 27096719
Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, et al. Prognostic value of somatostatin receptor expressing tumor volume calculated from (68)Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46:2244–51. https://doi.org/10.1007/s00259-019-04455-9 .
doi: 10.1007/s00259-019-04455-9
pubmed: 31350603
IARC. Digestive system tumours. WHO classification of Tumours, 5th Edition, Volume 1, WHO Classification of Tumours Editorial Board. 2019: ISBN-13 978-92-832-4499-8 https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Digestive-System-Tumours-2019
Orlhac F, Eertink JJ, Cottereau AS, Zijlstra JM, Thieblemont C, Meignan M, et al. A guide to ComBat harmonization of imaging biomarkers in multicenter studies. J Nucl Med. 2022;63:172–9. https://doi.org/10.2967/jnumed.121.262464 .
doi: 10.2967/jnumed.121.262464
pubmed: 34531263
pmcid: 8805779
Demsar JCT, Erjavec A, Gorup C, Hocevar T, Milutinovic M. Mozina M, Polajnar M, Toplak M, Staric A, Stajdohar M, Umek L, Zagar L, Zbontar J, Zitnik M, Zupan B, Orange: data mining toolbox in python. J Mach 2013.
Arakelyan J, Zohrabyan D, Philip PA. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): opportunities for personalized therapies. Cancer. 2021;127:345–53. https://doi.org/10.1002/cncr.33354 .
doi: 10.1002/cncr.33354
pubmed: 33270905
Hackeng WM, Brosens LAA, Kim JY, O’Sullivan R, Sung YN, Liu TC, et al. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2022;71:961–73. https://doi.org/10.1136/gutjnl-2020-322595 .
doi: 10.1136/gutjnl-2020-322595
pubmed: 33849943
Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, et al. Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases. Ann Surg. 2020;271:566–73. https://doi.org/10.1097/SLA.0000000000003022 .
doi: 10.1097/SLA.0000000000003022
pubmed: 30339629
Wang F, Xu X, Ye Z, Qin Y, Yu X, Ji S. Prognostic significance of altered ATRX/DAXX gene in pancreatic neuroendocrine tumors: a meta-analysis. Front Endocrinol. 2021; 12:691557. https://doi.org/10.3389/fendo.2021.691557 .
doi: 10.3389/fendo.2021.691557
pubmed: 34220718
pmcid: 8253224